TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd announced that the US Centers for Medicare & Medicaid Services (CMS) has set a reimbursement price for their PromarkerD test, a predictive diagnostic for diabetic kidney disease, at $390.75. This decision is a significant milestone for the company, enhancing their US launch strategy by facilitating broader patient access and strengthening discussions with private payers. The PromarkerD test, which can predict diabetic kidney disease up to four years before symptoms appear, has the potential to improve care for over 32 million adults in the US with diabetes, reduce healthcare costs, and drive adoption and commercial partnerships.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, is a medical technology company specializing in precision diagnostics and bio-analytical services. The company focuses on proteomics, which involves the large-scale study of proteins’ structure and function, aiming to improve disease treatment through innovative diagnostic tools.
Average Trading Volume: 284,973
Technical Sentiment Signal: Sell
Current Market Cap: A$54.83M
Learn more about PIQ stock on TipRanks’ Stock Analysis page.